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Manuscript receumerous deﬁnitions have been proposed for the diagnosis of myocardial infarction (MI) after coronary
revascularization. The universal deﬁnition for MI designates post procedural biomarker thresholds for deﬁning
percutaneous coronary intervention (PCI)-related MI (type 4a) and coronary artery bypass grafting (CABG)-related MI
(type 5), which are of uncertain prognostic importance. In addition, for both the MI types, cTn is recommended as the
biomarker of choice, the prognostic signiﬁcance of which is less well validated than CK-MB. Widespread adoption of
a MI deﬁnition not clearly linked to subsequent adverse events such as mortality or heart failure may have serious
consequences for the appropriate assessment of devices and therapies, may affect clinical care pathways, and may
result in misinterpretation of physician competence. Rather than using an MI deﬁnition sensitive for small degrees
of myonecrosis (the occurrence of which, based on contemporary large-scale studies, are unlikely to have important
clinical consequences), it is instead recommended that a threshold level of biomarker elevation which has been
strongly linked to subsequent adverse events in clinical studies be used to deﬁne a “clinically relevant MI.” The
present document introduces a new deﬁnition for “clinically relevant MI” after coronary revascularization (PCI or
CABG), which is applicable for use in clinical trials, patient care, and quality outcomes assessment. (J Am Coll
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ived July 12, 2013; accepted July 13, 2013.for assessing patient outcomes and for guiding quality
improvement initiatives. In 2007, a “universal deﬁnition” for
MI following coronary revascularization was proposed (2) and
recently revised in 2012 (3). In this document, a PCI-related
MI (type 4a) was deﬁned as an increase in cTn to >5 the
99th percentile of theURLduring the ﬁrst 48 h following PCI
(in patients with normal baseline cTn concentrations), plusSee page 1571either: 1) evidence of prolonged ischemia as demonstrated by
prolonged chest pain; or 2) ischemic ST-segment changes or
new pathological Q waves; or 3) angiographic evidence of
a ﬂow limiting complication; or 4) imaging evidence of new
loss of viable myocardium or new regional wall motion
abnormality. MI associated with CABG (type 5) was deﬁned
as an increase in cTn to>10 the 99th percentileURLduring
the ﬁrst 48 h following CABG (in patients with normal
baseline cTn concentrations), plus either: 1) new pathological
Q waves or new LBBB; or 2) angiographically documented
Abbreviations
and Acronyms
ACS = acute coronary
syndrome(s)
CABG = coronary artery
bypass graft
cMRI = cardiac magnetic
resonance imaging
LGE = late gadolinium
enhancement
MI = myocardial infarction
PCI = percutaneous coronary
intervention
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1564new graft or new native coronary
artery occlusion; or 3) imaging
evidence of new loss of viable
myocardium or new regional wall
motion abnormality. cTn were
considered the preferred
biomarker for detection of myo-
necrosis. However, the writing
committee also noted that these
deﬁnitions were arbitrarily chosen
and of uncertain clinical rele-
vance, and not grounded on
substantial scientiﬁc evidence
linking their occurrence to subse-quent adverse outcomes (2,3).
Assessment of post-PCI and -CABG biomarkers that are
strongly related to subsequent adverse patient outcomes is un-
doubtedly worthwhile. Conversely, applying undue significance
to peri-procedural biomarker elevations without prognostic
relevance may have unintended consequences on patient care,
physician and systems evaluation of PCI quality, and for the
development and appropriate assessment of new therapies.
Uncertainty among healthcare providers regarding the
interpretation of elevated cardiac biomarkers after success-
ful revascularization can lead to prolonged hospital stay and
unnecessary diagnostic or therapeutic interventions which
may result in iatrogenic complications and increased costs.
Lastly, adoption of a MI deﬁnition not based on mean-
ingful correlation with adverse consequences in clinical
trials may result in false conclusions regarding the relative
risk-beneﬁt ratio of comparative therapeutic strategies. The
present working group was thus tasked by SCAI Publica-
tion committee with developing a deﬁnition of peri-
procedural MI which, based on the preponderance of the
best scientiﬁc evidence, has clearly been shown to have
important prognostic signiﬁcance, hence termed a “clini-
cally relevant” MI. This document is endorsed by SCAI
publication committee, SCAI board of trustees, and SCAI
executive committee.
The present document will emphasize the deﬁnition of
MI after PCI procedures, but also refer to MI after CABG.
The present consensus recommendations are based heavily
on data from the largest, contemporary studies. The reader
should view this document as the best attempt of the writing
committee to inform and guide clinical practice and clinical
trial design in an area where the evidence base, while
substantial, is evolving.
Pathophysiology of Peri-Procedural Myonecrosis,
and the Potential for Confounding
The pathophysiology of myocardial necrosis following
revascularization procedures is multifactorial (4–8) (Online
Table 1). The mechanisms and risk factors associated with
post-PCI myonecrosis vary according to the deﬁnition of
myonecrosis (e.g., troponin vs. CK-MB elevations, and theselected threshold for abnormality) and the patient population
studied. Lee et al. (6) reported that a post-PCIMI (deﬁned as
cTn I elevation to>3 URL) was predicted by treatment of
type B2/C lesions and a thin-cap ﬁbroatheroma as assessed
by optical coherence tomography. Other studies have
shown a strong association between post-procedural
cardiac biomarker release and large atherosclerotic plaque
burden, large thrombus burden, coronary calciﬁcation, and
lesion eccentricity, as detected by angiography and intra-
vascular ultrasound imaging (7–9). As the extent and
complexity of coronary atherosclerosis is also an indepen-
dent predictor of mortality after PCI (10,11), the associa-
tion between post-PCI biomarker elevation and mortality
may be an epiphenomenon; that is, the linkage is explained
by the impact of the extent of atherosclerosis and lesion
complexity on mortality, not the biomarker elevation itself
(12). Thus, multivariable analysis incorporating both
clinical and angiographic variables, along with biomarker
elevations is necessary to determine whether the biomarker
elevation per se is an independent correlate of mortality.
Angiographically evident complications are not always
associated with sizable post-PCI biomarker elevations, and
biomarker elevations can occur without angiographic
complications (5,13). Muschart et al. (5) identiﬁed an
angiographic cause of post-PCI CK-MB>ULN (sidebranch
occlusion, distal embolization, slow ﬂow or no-reﬂow, intra-
procedural stent thrombosis, or coronary perforation) in only
60% of cases.Whether periprocedural biomarker elevations of
any level correlate with subsequent adverse events when
angiographic complications are absent is questionable.
Among 5,850 patients from six stent trials, even large
biomarker elevations (CK-MB >8 ULN) had no prog-
nostic impact unless associated with overt angiographic
complications, questioning the relevance of isolated measures
of myonecrosis (14). The frequency of peri-procedural MI
depends on the type of cardiac biomarker being measured
(cTn vs. CK-MB), the frequency and timing of biomarker
determinations, and the threshold that deﬁnes a MI (15).
Moreover, in most clinical studies, the upper range of cardiac
biomarkers has been deﬁned as a multiple of the ULN of
the local laboratory assay. In contrast, the universal deﬁnition
recommends evaluating biomarker elevations based on the
99th percentile limit of the reference value distribution (99th
upper reference limit [URL]) (2,3), which is an even more
sensitive measure. However, use of the URL is problematic
because most assays do not have the sensitivity to consistently
measure cTn in the blood of apparently healthy individuals,
with a high proportion of the values being below the method’s
detection limit. Moreover, the 99th URL for cTn can vary
depending on the reference population used, and its sample
size. A marked difference can also be observed between the
99th URL obtained using plasma versus that obtained with
serum. Finally, interferences with cTn measurement may
occur with assays having increased analytical sensitivity (16).
As a result of these limitations, most laboratories have
established a normal reference range deﬁned as the set of
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prior studies have used this locally derived ULN when
examining the prognostic relevance of CK-MB and troponin
elevations.
Importance of Pre-Procedure
Cardiac Biomarker Elevation
Prior studies in which pre-PCI and post-PCI cTn elevations
were analyzed have reported that only pre-procedure cTn
elevations are correlated with subsequent mortality (Online
Table 2). In an analysis of 5,487 patients undergoing non-
emergent PCI at the Mayo Clinic (17), an abnormal pre-
PCI cTnT level independently predicted death (median
follow-up of 28 months), but the occurrence of PCI-related
myonecrosis did not, whether deﬁned by >3 elevation in
cTn or CK-MB. In a separate study, baseline cTn was
>ULN in 6.0% of 2,382 patients undergoing elective PCI,
and was an independent predictor of in-hospital death or MI
(18). Thus, interpretation of post-PCI biomarker elevations
may be erroneous if baseline levels are not assessed.
The accurate diagnosis of post-PCI MI is challenging
among patients with baseline biomarker elevations. The
2012 universal deﬁnition states that “If the baseline cTn
values are elevated and are stable or falling, then a rise of
>20% is required for the diagnosis of a type 4a MI, as with
reinfarction” (3). These recommendations were based on
recent data from the TRITON–TIMI-38 which suggest
that, when PCI is delayed after MI until biomarker
concentrations are falling or have normalized, re-elevation of
cardiac biomarker values may have long-term signiﬁcance
(19). The diagnosis of peri-PCI MI in this study, however,
was preferentially based on CK-MB measures, and residual
confounding cannot be excluded, as discussed in the next
section. As such, the prognostic relevance of post-PCI
biomarkers in the patient with a recent ACS have not
been sufﬁciently validated to be applied clinically.
cTn Versus CK-MB Elevation After
Coronary Revascularization
cTn is a more sensitive and speciﬁc biomarker for myonec-
rosis than is CK-MB (20,21), and CK-MB is no longer
measured at some institutions. This transition was made
prior to thorough understanding of the prognostic implica-
tions of cTn elevations after coronary revascularization.
Numerous studies have suggested a stronger association with
post-PCI CK-MB and subsequent cardiovascular events
than with cTn elevation (Online Table 3). Furthermore, the
greater sensitivity of cTn for myonecrosis markedly increases
the rate of type 4a MI. Among 4,930 patients undergoing
elective coronary stenting, MI occurred in 7.2% using a CK-
MB criteria of 3 ULN and in 24.3% using a cTn criteria
of 3 ULN (22). Lastly, changes in myocycte membrane
permeability resulting from prolonged myocardial ischemia
and other causes is sufﬁcient for the release of cTn from thefree cytosolic pool of myocytes without structural damage,
explaining troponin elevations during rapid atrial pacing,
supraventricular tachycardia and noncardiac conditions,
including exercise and renal disease (23).
The recommendation to use cTn rather than CK-MB
and a cutoff of 3 the 99th percentile URL for the diag-
nosis of post-PCI MI in the original universal deﬁnition of
MI was described as arbitrary by the authors (2). The
revised universal deﬁnition has raised the cTn cutoff to 5
the 99th percentile URL and added the requirement for
clinical, ECG or angiographic changes for the diagnosis of
post-PCI MI, likely increasing the speciﬁcity for MI (3).
Although these revisions are a step in the right direction,
they are still admittedly arbitrary and do not sufﬁciently
weigh the contemporary evidence base from which the
criteria for a “clinically relevant MI” (one associated with an
adverse prognosis) should be derived.
The relationship between biomarker elevations after
revascularization and mortality is controversial, and the
evidence base for this association has evolved over the last
15 years. When analyzed as a continuous variable above
a threshold, a small incremental risk with cardiac biomarker
elevation is noted (Online Table 3). However, this type of
analysis is misleading because it lumps large biomarker
elevations with small elevations. When analyzed in cate-
gories of incrementally increasing biomarker elevations,
most contemporary PCI studies have reported associations
between peri-procedural myonecrosis and mortality only for
very large infarcts (Online Table 3). Among 7,147 patients
undergoing PCI at Washington Hospital Center, 37.3%
had a post-PCI CK-MB >ULN; however, only Q-wave
MI or non-Q-wave MI with a peak CK-MB of >8 ULN
correlated with increased 2-year mortality (24). Among
3,478 patients undergoing stent implantation at the Cleve-
land Clinic, post-PCI CK-MB >ULN was detected in
24%; only CK-MB >10 ULN was signiﬁcantly associated
with increased 1-year mortality (25). In the EVENT registry
(n ¼ 6,347), only CK-MB 50 mg/ml (w10 ULN) was
associated with increased 30-day and 1-year mortality after
nonemergent PCI (26). In the 3,687 patient SPIRIT IV
trial, CK-MB >3 ULN and cTn >3 ULN were present
in 5.4% and 19.7% of stented patients, respectively; there
was no relationship between any level of either biomarker
and 2-year mortality, even >10 ULN (27). Some have
argued that small peri-procedural MIs will only have clinical
impact with long-term follow-up. However, there was no
relationship between protocol-deﬁned MI and 5-year
mortality among 5,467 patients with ACS in whom PCI
was performed from three randomized trials (28).
The TRITON–TIMI-38 investigators did report a rela-
tionship between type 4a MI (deﬁned as CK-MB >3
URL on two samples or >5 on a single sample) and
6-month cardiovascular mortality (19). However, this risk
was not adjusted for the complexity of underlying CAD or
treated lesions. Similarly, multivariable analysis to account
for recent MI, unstable angina, thrombotic or complex
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was not performed in many of the earlier studies examining
the relationship between peri-procedural biomarker eleva-
tion and mortality. As previously discussed, mortality after
CK-MB elevation may reﬂect the underlying extent of
atherosclerosis and lesion complexity requiring treatment
rather than the biomarker elevation per se (12). Similarly,
procedural urgency and multivessel PCI is more common in
patients with small post-PCI cTn elevations, suggesting
complex and extensive atherosclerosis as underlying the
mortality associated with microinfarcts rather than minor
myocardial injury (29). The association of low-level bio-
marker elevations with mortality in early studies was always
difﬁcult to reconcile with traditional concepts relating large
infarctions and depressed global cardiac function as major
determinants of prognosis. Conversely, nearly all large-scale,
contemporary studies have shown that only a substantial
amount of myonecrosis, typically associated with CK-MB
>10 ULN or new Q-wave infarction, is required to
adversely impact survival.
The requirement for a large biomarker increase to signify
a clinically relevant MI after PCI contrast with type I
(spontaneous) MI, in which even minor elevations of cTn
have repeatedly and strongly been associated with high rates
of death and subsequent MI during follow-up (17). The
adverse prognosis following type I MI is not only due to the
immediate impact of myocardial injury, but also reﬂects the
consequences of plaque rupture occurring in an uncontrolled
setting. Multifocal plaque instability and persistent systemic
inﬂammation are also often present and increase the risk of
future events (30–32). Conversely, peri-procedural myo-
necrosis is induced by a single procedure in a controlled
setting, and in most cases its consequences (if any) are
immediately addressed.
Insight From Cardiac Magnetic Resonance
Imaging Studies
cMRI is increasingly being used to evaluate the extent of
coronary hypoperfusion and myonecrosis (33,34). Large
compared to small or absent cMRI defects are strongly
associated with subsequent mortality (33). cMRI studies
have demonstrated poor discrimination of cTn elevations for
myocardial injury. Using late gadolinium enhancement
(LGE), Lim et al. (35) reported the sensitivity, speciﬁcity
and positive predictive value of cTn I-deﬁned MI >3 the
99th percentile URL to be 100, 22, and 19%, respectively.
The analogous ﬁndings using CK-MB-deﬁned MI>3 the
99th percentile URL were 60, 93, and 60%, respectively,
demonstrating that cTn is overly sensitive and identiﬁes
many patients without objective evidence of cMRI-detected
myocardial injury. While small levels of cTn elevation may
represent myonecrosis not detectable by cMRI, the prog-
nostic signiﬁcance of such small elevations has not been
demonstrated. The authors further reported that chang-
ing the cTn I threshold for MI diagnosis to 40 the99th percentile URL would greatly enhance speciﬁcity
(93%) without reducing sensitivity (100%). This w13
bioequivalence ratio of cTn:CK-MB is even greater than
the w7-fold ratio reported from the EVENT registry in
which a cTn threshold >20 ULN was associated with
similar mortality rates as a >3 CK-MB increase (22).
These data conﬁrm that very different thresholds for CK-
MB and cTn after PCI must be considered to represent
similar levels of myonecrosis.Recommendation for a Deﬁnition of “Clinically
Relevant MI” After Coronary Revascularization
Patients with normal baseline cardiac biomarkers. Com-
pilation of the best medical evidence to date does not support
use of the universal deﬁnition as the optimal criterion to
identify clinically relevant post-PCI MI events. Rather,
most contemporary studies support a post-PCI elevation of
CK-MB to 10 ULN as being clinically relevant. While
there may be some incremental value of identifying very
small post-PCI infarcts, speciﬁcally those that occur with
angiographically evident complications, more study is re-
quired in this regard, with angiographic core laboratory
veriﬁcation of events. Similarly, almost all clinical studies to
date have reported the impact of biomarker elevation in
relation to a multiple of the ULN, not the 99th percentile of
the URL. Thus, absent such studies, a clinically relevant MI
occurring in the post-PCI period should be deﬁned as that
resulting in a CK-MB 10 ULN. A lower threshold
(5 ULN) may be accepted in the patient in whom new
pathologic Q-waves in 2 contiguous leads (or new persis-
tent LBBB) develop post-PCI, although further study is
required to validate this threshold in the setting of new Q-
waves.
A threshold post-PCI level of cTn above which long-term
prognosis is affected has not been established, and thus
CK-MB is strongly preferred to assess clinically relevant
post-PCI MI events. If CK-MB levels are unavailable,
a reasonable cTn (I or T) value to substitute to diagnose
a type 4a MI would be cTn of 70 ULN, based on the 7:1
troponin:CK-MB ratio noted to have approximate similar
clinical implications (22). As discussed, this 7:1 ratio is
a conservative estimate when examining the results from
imaging studies (35). Thus, in patients with normal baseline
cTn and without an acute coronary syndrome (ACS) (i.e.,
rising biomarker levels are not suspected), a clinically rele-
vant MI post-PCI is diagnosed by a new biomarker eleva-
tion of CK-MB to 10 ULN or cTn (I or T) to 70
ULN (or by CK-MB to 5 ULN or cTn to 35 ULN
plus the development of new pathologic Q-waves in 2
contiguous leads or LBBB).
Patients with elevated baseline cardiac biomarkers.
Accurately diagnosing post-PCI MI in the setting of
elevated baseline biomarkers is problematic, and depends on
whether the peak level has been documented. This requires
assessment of serial biomarker levels. Often, however,
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biomarker level is obtained, or when serial biomarkers show
continued escalation, in which case diagnosing post-PCI
MI on the basis of biomarker levels alone is impossible.
Thus, based on the thresholds determined from large-scale
studies in which baseline biomarkers were normal, the
following recommendations are made to diagnose post-PCI
MI in ACS patients in whom the baseline level has not
returned to normal: 1) In patients with elevated cTn (or
CK-MB) in whom the biomarker levels are stable or falling,
there should be a new CK-MB elevation by an absolute
increment of 10 ULN (or 70 ULN for cTn I or T)
from the previous nadir level; 2) In patients with elevated
cTn (or CK-MB) in whom the biomarker levels have not
been shown to be stable or falling, there should be a further
rise in CK-MB or troponin beyond the most recently
measured value by an absolute increment of 10 ULN in
CK-MB or 70 ULN in cTn plus new ST-segment
elevation or depression plus signs consistent with a clini-
cally relevant MI, such as new onset or worsening heart
failure or sustained hypotension. Chest pain alone is not
speciﬁc enough for substantial myonecrosis to be used as
a criterion. We acknowledge, however, that further studies
are required to reﬁne the best diagnostic criteria in patients
with elevated baseline biomarkers.
These criteria are summarized in Table 1. Practical
recommendations of a clinically relevant deﬁnition of MI for
assessment of cardiac biomarkers after PCI, its use as
a quality of care indicator, and its impact on clinical trial
design are discussed in the Online Appendix.Post-CABG Myocardial Infarction
Applying the 2007 universal deﬁnition of post CABG MI
(type 5), 42% to 82% of patients have cardiac biomarker
elevation 5 the URL (36,37), but only 4% to 7% have the
additional electrocardiographic evidence needed to meet the
deﬁnition of post-CABG MI (38,39). In the 2012 revised
version of the universal deﬁnition the threshold for diagnosis
of post CABG MI (type 5) was increased to >10 the 99th
percentile of the URL from a normal baseline cTn value and
in addition requires either: 1) new pathological Q-waves or
new LBBB; or 2) angiographically documented new graft or
new native coronary artery occlusion; or 3 imaging evidenceTable 1 Deﬁnition of Clinically Relevant MI After Both PCI and CABG
1. In patients with normal baseline CK-MB The peak CK
ULN, or to
LBBB, OR i
measured
with new p
2. In patients with elevated baseline CK-MB (or cTn) in whom the
biomarker levels are stable or falling
The CK-MB (o
the most r
3. In patients with elevated CK-MB (or cTn) in whom the biomarker
levels have not been shown to be stable or falling
The CK-MB (o
new ST-seg
as new onsof new loss of viable myocardium or new regional wall
motion abnormality (3). The implications of this change on
the frequency and prognostic implications of post-CABG
MI are unclear.
Although some studies have suggested that only large
myocardial biomarker elevations after CABG are clinically
important (40–42), others have demonstrated that evenmodest
CK-MB elevations after CABG may be associated with
increased mortality (43–48). Most recently, a large patient-
level meta-analysis demonstrated a doubling of short- and
long-term mortality in patients in whom cardiac biomarker
measurements within 24 hr after CABG rose to 4 to 5
ULN (49). After multivariable adjustment, 30-day mortality
was signiﬁcantly increased in patients with a post-CABGCK-
MB of >5 ULN and with a cTn >40 ULN; an expo-
nential rise in mortality was seen with >40 and >100
increases in CK-MB and cTn above the ULN, respectively.
Additional studies have suggested that early biomarker
release (occurring within 1 h post-CABG) may be a
meaningful predictor of in-hospital mortality (50), while
elevation in later samples (with 48 h post-CABG) appear
to be a stronger predictor of long-term mortality (51).
Modest-sized studies utilizing cMRI suggest that 28% to
44% of patients post-CABG have detectable myonecrosis
(50–52). These studies have shown a moderate correlation
between post-CABG cardiac biomarker elevation and the
extent of new myocardial necrosis observed by LGE.
Moreover, these studies have demonstrated that new areas
of LGE after CABG have greater prognostic impact when
accompanied by biomarker elevation of 5 ULN
compared to <5 ULN.
Similar to the post-PCI population, the majority of the
studies have evaluated the prognostic signiﬁcance of post-
CABG cardiac biomarker elevations using CK-MB. cTn
measurements may be an overly sensitive marker of
myocardial necrosis in this setting. Remmpis et al. have
shown that cTn release from nonstructurally bound cyto-
solic pools may lead to systemic troponin elevations
without cardiomyocyte injury (53, Online Refs. 54–99).
“Washout” of this cytosolic component of troponin,
secondary to surgery-induced increased cell permeability
without cellular death, could result in cTn rise in the ﬁrst
few hours after surgery without irreversible myocardial
injury.Procedures
-MB measured within 48 hours of the procedure rises to 10  the local laboratory
5  ULN with new pathologic Q-waves in 2 contiguous leads or new persistent
n the absence of CK-MB measurements and a normal baseline cTn, a cTn (I or T) level
within 48 hours of the PCI rises to 70  the local laboratory ULN, or 35  ULN
athologic Q-waves in 2 contiguous leads or new persistent LBBB.
r cTn) rises by an absolute increment equal to those levels recommended above from
ecent pre-procedure level.
r cTn) rises by an absolute increment equal to those levels recommended above plus
ment elevation or depression plus signs consistent with a clinically relevant MI, such
et or worsening heart failure or sustained hypotension.
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biomarkers for CABG versus a 5 increase for PCI as
recommended in the 2012 universal deﬁnition is not clearly
substantiated (3). Nonetheless, as a working deﬁnition we
support this threshold to diagnose a clinically relevant MI
post CABG. However, CK-MB is the preferred biomarker,
and if a cTn threshold must be used, 70 is reasonable.
Thus, the recommendations for the preferred biomarker
type and threshold after PCI and CABG are harmonized
(Table 1). While not currently recommended as part of this
deﬁnition (given the absence of data), the use of post-
CABG ECGs, indices of hemodynamic instability, and
imaging studies demonstrating new wall motion abnormal-
ities have been suggested to complement biomarker eleva-
tions post-CABG to improve speciﬁcity. Additional studies
in this regard are warranted.
Limitations and Future Directions
The currently recommended deﬁnition of a clinically rele-
vant MI, while admittedly imperfect, is based on the best
scientiﬁc evidence presently available. Nonetheless, we
acknowledge the need for further research, and revision of
this deﬁnition as new data becomes available. In particular,
given the greater speciﬁcity of cTn for cardiac myonecrosis
compared to CK-MB, additional investigation should focus
on determining the threshold at which cTn measurements
have prognostic value after PCI and CABG (and whether
in this regard there are important differences between cTnT
and cTnI).
One of the greatest barriers in interpreting the current
data is the lack of patient-level, vessel-level and lesion-level
characteristics, making it difﬁcult to attribute post-PCI
biomarker elevations to adverse events rather than repre-
senting a surrogate marker of higher risk patients. Future
research should consider the relationship between plaque
burden, coronary anatomy and complex intervention on
the incidence of peri-procedural MI. Until the issues
surrounding diagnosis and prognosis associated with peri-
procedural myonecrosis and adverse events can be resolved,
our ability to effectively risk-stratify and optimally manage
patients undergoing coronary revascularization will remain
limited, and evaluation of the utility and cost-effectiveness
of new therapies will be imperfect. It is our belief that the
use of the deﬁnition of clinically relevant MI introduced in
this document is a ﬁrst step toward addressing these issues.
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